Scaling Spray Drying for Tomorrow’s Therapies in a Changing Global Market
Abstract: Modern drug development is being tested on two fronts: molecules are increasingly difficult to formulate, and global manufacturing routes are increasingly difficult to rely on. Poor water solubility and limited physical stability continue to slow many small‑molecule and peptide programs, while shifting trade policies and logistics constraints add cost and risk across fragmented supply chains. This executive summary explores how integrating large‑scale, domestic spray drying capacity earlier in development can help sponsors accelerate timelines, improve cost efficiency for high‑volume therapies, and reduce risk tied to international manufacturing disruption. It also outlines the role of spray drying in enabling spray‑dried amorphous systems and amorphous solid dispersions (ASDs), key scale‑up considerations, and why selecting a CDMO partner with the right capacity and scientific track record can help bridge feasibility to commercial execution.